Invention Grant
- Patent Title: Myeloid differentiation factor 2 (MD2) signaling and modulation
-
Application No.: US17734432Application Date: 2022-05-02
-
Publication No.: US12054517B2Publication Date: 2024-08-06
- Inventor: Yoshikazu Takada , Yoko Takada
- Applicant: The Regents of the University of California
- Applicant Address: US CA Oakland
- Assignee: The Regents of the University of California
- Current Assignee: The Regents of the University of California
- Current Assignee Address: US CA Oakland
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: C07K14/00
- IPC: C07K14/00 ; A61P29/00 ; C12N15/63

Abstract:
The present invention resides in the discovery that the specific interaction between Myeloid Differentiation factor 2 (MD2) and integrin, especially integrin αvβ3, is involved in cellular signaling mediated by MD2-integrin, such as inflammatory response including sepsis. Thus, this invention provides for a novel method for inhibiting integrin signaling by using an inhibitor of MD2-integrin binding, such as a dominant negative mutant of MD2 without integrin-binding capability. A method for identifying inhibitors of MD2-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, host cells, and corresponding compositions for inhibiting MD2-integrin signaling.
Public/Granted literature
- US20220356211A1 MYELOID DIFFERENTIATION FACTOR 2 (MD2) SIGNALING AND MODULATION Public/Granted day:2022-11-10
Information query